| Project/Area Number |
20K07805
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 52010:General internal medicine-related
|
|---|
| Research Institution | Ehime University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
茂木 正樹 愛媛大学, 医学系研究科, 教授 (20363236)
三宅 吉博 愛媛大学, 医学系研究科, 教授 (50330246)
|
|---|
| Project Period (FY) |
2020-04-01 – 2024-03-31
|
| Project Status |
Completed (Fiscal Year 2023)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2022: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2021: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2020: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Keywords | microRAN / 血管性認知機能障害 / microRNA / 認知症 / 血管障害 / エクソソーム |
|---|
| Outline of Research at the Start |
認知症を血管疾患の延長と捉え、血液脳関門の破綻に着目した病態メカニズムの解明を足がかりに、microRNA等に着目して、認知症の新たな診断方法や血液脳関門破綻を標的とした新たな作用機序による創薬開発等へ挑戦する研究である。
|
| Outline of Final Research Achievements |
We focused on the association between blood-brain barrier disruption and the pathology of dementia, and evaluated the utility of microRNA as diagnostic biomarkers. While miR-511-3p was found to be unlikely to serve as an effective diagnostic marker, miR-501-3p showed potential as an indicator of both arteriosclerosis and mild cognitive impairment. Specifically, high levels of blood exosomal miR-501-3p were associated with greater progression of arteriosclerosis and more frequent detection of mild cognitive impairment. This investigation suggests that blood exosome microRNA levels could become useful diagnostic markers for detecting dementia.
|
| Academic Significance and Societal Importance of the Research Achievements |
動脈硬化や軽度認知機能障害の有用なヒトバイオマーカーである可能性を示した点は学術的に重要です。これにより、新たな診断法や治療法の開発に寄与することが期待されます。また、血液検査が認知症の早期発見と予防に役立つ可能性があり、非侵襲的な検査法として普及すれば、患者の負担を軽減し、医療コストの削減にも寄与する社会的な意義があります。
|
